ADRB2 and hydrops fetalis: β-blockers have been tested in numerous molecular and clinical studies, and they currently represent one of the cornerstones in the therapy of HF, though it is still debated whether they act by blocking or by resensitizing the β-AR system (Vinge et al., 2008).